Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FK506 Phase 4 Study: A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients

NCT00319917 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00319917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00319917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FK506 Phase 4 Study: A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2006
Completion date
October 31, 2008
Enrollment
123 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis